The shares of Dr. Reddy’s Laboratories were up 3.4 per cent to Rs 4,553.70 in today’s trade.

The company and its wholly-owned subsidiary have launched Dr. Reddy’s Fesoterodine Fumarate Extended-Release Tablets, a generic therapeutic equivalent to Toviaz® (fesoterodine fumarate), which USFDA has approved. These tablets are available in 4 mg and 8 mg tablets, each in bottle count sizes of 30.

According to IQVIA, the Toviaz brand had approximately $211 million in MAT sales.

• India Approves 25 LMT Wheat, 5 LMT Sugar Export Quota
• US Core Inflation Seen at 5-Year Low Ahead of Friday Report
• Shilpa Medicare Signs NCE Pact with NXI; Shares End 1% Up
• Dilip Buildcon Wins Rs 124 Cr PNGRB ATF Project; Stock Down 3.5%
• Natco Pharma Shares Slump 2% as the USFDA Issued 7 Observations

Last week USFDA completed a pre-approval inspection (PAI) of the formulation of the company that manufactured facility FTO11 in Srikakulam, Andhra Pradesh. USFDA had issued a Form 483 mentioning two observations and will address them within the stipulated timeline.

Previously, Dr Reddy’s has performed in the market by gaining 4 per cent, against an 8 per cent downfall in the S&P BSE Sensex. Comparatively, the shares have slipped 17 per cent in a year to rise 3.5 per cent in the benchmark index.